Medicinova (MNOV) vs Oncolytics Biotech (ONCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Medicinova (MNOV) has outperformed Oncolytics Biotech (ONCY) over the past year, gaining 26.2% versus a loss of 57.5%. Over five years, MNOV leads with a -59.7% price change compared with -75.5% for ONCY. Medicinova is the larger company by market cap ($74.8 million vs $73.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNOV | ONCY |
|---|---|---|
| Share price | $1.52 | $0.557 |
| Market cap | $74.82M | $73.03M |
| 1-day change | -1.30% | +2.31% |
| YTD return | +17.56% | -37.43% |
| 1-year return | +26.23% | -57.47% |
| 5-year return | -59.69% | -75.48% |
| EPS (TTM) | $-0.21 | $-0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.90 | $1.32 |
| 52-week low | $1.17 | $0.525 |
| Distance from 52-week high | -61.03% | -57.80% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +442.76% | +645.06% |
| Average volume | 322.57K | 1.08M |
| Shares outstanding | 49.22M | 131.12M |
| Employees | 6 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNOV has outperformed ONCY by 83.7 percentage points over the past year.
About Medicinova
MNOV stock →MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Oncolytics Biotech
ONCY stock →Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
MNOV vs ONCY FAQ
Which is bigger, Medicinova or Oncolytics Biotech?
Medicinova (MNOV) is larger, with a market capitalization of $74.82M compared with $73.03M for Oncolytics Biotech (ONCY).
Which stock has performed better over the past year, MNOV or ONCY?
MNOV returned +26.23% over the past 12 months, compared with -57.47% for ONCY (price return, excluding dividends). Past performance does not predict future results.
Are Medicinova and Oncolytics Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.